Amarin Corporation

Amarin Corporation Receivables

The Accounts Receivable of Amarin Corporation (AMRN) as of Nov 19, 2026 is 126.83 M USD. In the previous year, Accounts Receivable was 122.28 M USD — a change of 3.72% (higher).

Receivables

126.83 MUSD

YoY

3.72%

Last updated:

Accounts Receivable of Amarin Corporation is 2025 126.83 M USD. Accounts Receivable of Amarin Corporation was 2024 122.28 M USD. It decreases by 3.72% higher compared to the previous year.

The Amarin Corporation Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
66.50 M USD
Jan 1, 2019
116.40 M USD
Jan 1, 2020
154.60 M USD
Jan 1, 2021
163.70 M USD
Jan 1, 2022
131.00 M USD
Jan 1, 2023
133.56 M USD
Jan 1, 2024
122.28 M USD
Jan 1, 2025
126.83 M USD
The Amarin Corporation Receivables history
YEARReceivablesYoY
126.83 MUSD+3.72%
122.28 MUSD-8.45%
133.56 MUSD+1.96%
131.00 MUSD-19.98%
163.70 MUSD+5.89%
154.60 MUSD+32.82%
116.40 MUSD+75.04%
66.50 MUSD+46.80%
45.30 MUSD+126.50%
20.00 MUSD+44.93%
13.80 MUSD+76.92%
7.80 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amarin Corporation Stock analysis

What does Amarin Corporation do? Amarin Corporation PLC generates revenue primarily through the sale of Vascepa (icosapent ethyl) capsules, approved by the FDA for reducing triglyceride levels in patients with severe hypertriglyceridemia. The company sells Vascepa to wholesalers, regional wholesalers, and specialty pharmacy providers, collectively referred to as distributors, who then resell the product to retail pharmacies for patient and healthcare provider use. The MARINE indication, derived from the MARINE study, is the key approved use driving sales in the cardiovascular health segment. Amarin's commercial strategy centers on the Vascepa segment, focusing on the development and commercialization of this therapeutic. The firm's lead product, Vascepa, is positioned as an adjunct to diet for treating severe hypertriglyceridemia, targeting healthcare providers and patients through a distribution network of wholesalers and specialty pharmacies. This model ensures Vascepa reaches retail pharmacies where it is dispensed to end users. Amarin Corporation is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amarin Corporation stock

Accounts Receivable of Amarin Corporation is 126.83 M USD in 2025.

Accounts Receivable of Amarin Corporation changed from 122.28 M USD to 126.83 M USD, representing a 3.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Amarin Corporation since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Amarin Corporation historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Amarin Corporation

All Key Metrics — Amarin Corporation